Infliximab, azathioprine, or combination therapy for Crohn's disease.
Ruffolo
Cesare
C
Scarpa
Marco
M
Bassi
Nicolò
N
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000069285:Infliximab; D009369:Neoplasms / Q000139:chemically induced
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab; D001379:Azathioprine